This study investigated the feasibility of predicting the neutropenia-related effects of a therapy that combines the investigational drug BI 2536 (inhibitor of Polo-like kinase 1) and pemetrexed, an approved anticancer drug. Predictions were arrived at using the pharmacokinetic/pharmacodynamic (PK/PD) parameters of each of the drugs obtained from monotherapy studies and assuming that the neutropenic effect is additive when the drugs are administered as a combination therapy. Subsequently, a PK/PD model was developed to determine whether this assumption of additive effect was reasonable in relation to these two drugs. All analyses and simulations were performed using the population approach in NONMEM, version VI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/clpt.2010.148 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The complex relationship between large granular lymphocyte leukemia and rheumatic disease.
Expert Rev Clin Immunol
March 2024
Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Introduction: Large granular lymphocytic (LGL) leukemia is a rare lymphoproliferative disorder characterized by an expansion of clonal T or NK lymphocytes. Neutropenia-related infections represent the main clinical manifestation. Even if the disease follows an indolent course, most patients will ultimately need treatment in their lifetime.
View Article and Find Full Text PDFHybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol
January 2024
Clinical Research Unit.
Article Synopsis
- Acute lymphoblastic leukemia (ALL) treatment for children includes a 2-year outpatient maintenance therapy (MT), which transitioned from entirely outpatient to a hybrid e-clinic/outpatient model over 8 years.
- The study analyzed data from 478 children on MT, finding that the hybrid model reduced outpatient visits by about two-thirds while maintaining treatment effectiveness and increasing dose intensity.
- Families reported significant satisfaction with the hybrid service, which also cut maintenance treatment costs by roughly 50%, demonstrating it as an effective and less burdensome approach for patients.
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients.
Oncologist
April 2024
Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
Article Synopsis
- CDK4/6 inhibitors are effective for hormone-positive metastatic breast cancer but commonly cause neutropenia, especially in Asian patients.
- A study of 105 Taiwanese patients revealed a very high incidence of neutropenia related to palbociclib treatment, with an interesting association between early neutropenia and worse outcomes, and severe neutropenia linked to better results.
- Genetic analysis found notable differences in SNP frequencies that could help explain the higher prevalence of neutropenia in certain populations, and drug levels were monitored in patients receiving peritoneal dialysis.
Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes.
Cancer Treat Res Commun
May 2023
Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Electronic address:
Article Synopsis
- The study investigates real-world treatment strategies for neutropenia in patients taking palbociclib, focusing on their impact on progression-free survival (PFS) against outcomes in clinical trials.
- Data from 229 patients with HR-positive, HER2-negative metastatic breast cancer were analyzed, revealing different treatment modifications compared to the PALOMA-3 clinical trial, but no significant effect on PFS.
- Patients deemed ineligible for the PALOMA-3 trial had shorter PFS, emphasizing that real-world outcomes may differ from those observed in clinical trials.
Neutropenia-related aspergillosis in non-transplant haematological patients hospitalised under ambient air versus purified air conditions.
Mycoses
June 2023
Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Background: To reduce the risk of invasive aspergillosis (IA), air purification by high-efficiency particulate air filtration and laminar air flow (HEPA/LAF) is standard of care in allogeneic blood stem cell transplantation. Its use in non-transplant haematological patients is inconsistent.
Objectives: We sought to assess the incidence and outcome of pulmonary IA in non-transplant patients with life-threatening neutropenia by comparing an ambient air hospitalisation period (2008-2011) with a subsequent HEPA/LAF hospitalisation period (2012-2014).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!